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Contractile functionPhosphatase and tensin homolog (PTEN) deleted from chromosome 10 has been implicated in the maintenance
of cardiac homeostasis although the underlyingmechanism(s) remains elusive.We generated amurinemodel of
cardiomyocyte-speciﬁc knockout of PTEN to evaluate cardiac geometry and contractile function, as well as the
effect of metformin on PTEN deﬁciency-induced cardiac anomalies, if any. Cardiac histology, autophagy and
related signaling molecules were evaluated. Cardiomyocyte-speciﬁc PTEN deletion elicited cardiac hypertrophy
and contractile anomalies (echocardiographic and cardiomyocyte contractile dysfunction) associated with
compromised intracellular Ca2+ handling. PTENdeletion-induced cardiac hypertrophy and contractile anomalies
were associated with dampened phosphorylation of PTEN-inducible kinase 1 (Pink1) and AMPK. Interestingly,
administration of AMPK activator metformin (200 mg/kg/d, in drinking H2O for 4 weeks) rescued against
PTEN deletion-induced geometric and functional defects as well as interrupted autophagy and autophagic ﬂux
in the heart. Moreover, metformin administration partially although signiﬁcantly attenuated PTEN deletion-
induced accumulation of superoxide. RNA interference against Pink1 in H9C2 myoblasts overtly increased
intracellular ATP levels and suppressed AMPK phosphorylation, conﬁrming the role of AMPK as a downstream
target for PTEN–Pink1. Further scrutiny revealed that activation of AMPK and autophagy using metformin and
rapamycin, respectively, rescued against PTEN deletion-inducedmechanical anomalies with little additive effect.
These data demonstrated that cardiomyocyte-speciﬁc deletion of PTEN leads to the loss of Pink1–AMPK
signaling, development of cardiac hypertrophy and contractile defect. Activation of AMPK rescued against
PTEN deletion-induced cardiac anomalies associated with restoration of autophagy and autophagic ﬂux. This
article is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Compromised insulin signaling and insulin resistance are well
known to contribute to the increased prevalence ofmetabolic syndrome
and cardiovascular diseases [1–3]. Not surprisingly, pharmacological
strategy targeting insulin signaling cascade has become an attractive
therapeutic remedy in the management of cardiovascular in particular
heart diseases [2,4]. Among various components in insulin signaling
cascade, phosphatase and tensin homolog deleted from chromosomey and protein quality control in
ege of Health Sciences, Laramie,
2953.10 (PTEN) may represent one of the novel signaling targets in the
regulation of insulin sensitivity. It has been reported that PTEN
negatively regulates insulin signaling by dephosphorylating phosphatidyl
inositol triphosphate to ultimately terminate Akt activation [5].
Individuals possessing haploinsufﬁciency of PTEN display enhanced
insulin sensitivity despite increased body mass [6]. PTEN deletion
improves insulin signaling in skeletal muscles albeit prompting
cardiomyocyte dysfunction and hypertrophy [7–9]. This is somewhat in
line with the notion that overactivation of Akt leads to the development
of cardiac hypertrophy and contractile dysfunction over time [9,10].
Up-to-date, the signaling regulatory machineries in cardiac homeo-
stasis remain elusive for PTEN. One possible pathway participating in
PTEN signaling may be PTEN-inducible kinase 1 (Pink1). Pink1 is a
kinase essential to cardiac homeostasis in physiological conditions, as
deletion of which results in cardiac hypertrophy and dysfunction in a
manner reminiscent to PTEN deﬁciency [11]. Pink1 knockout may
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oxidative stress [11]. As implicated by the nomenclature, expression of
Pink1 is tightly correlated with the PTEN activity, where decreased
PTEN results in loss of Pink1 [12]. The apparent connection and
similarity in cardiac phenotype upon genetic deletion between these
two signaling molecules depict an essential role of the PTEN–Pink1
pair in the maintenance of cardiac homeostasis under both physiological
and pathophysiological conditions.
AMP-activated protein kinase (AMPK) is a critical energy fuel sensor.
AMPK regulatesmetabolism via promoting glycolysis, glucose transport
and fatty acid oxidation [13]. AMPK is activated following a rise in
intracellular AMP/ATP ratio as well as through protein kinases such as
LKB1 and CaMKKβ [14]. More recent ﬁnding suggests a pivotal role of
AMPK in the regulation of cardiac autophagy, a cellular process essential
to break down cellular proteins and organelles to be recycled for
production of ATP and nutrients [15]. However, little information is
available with regards to the role of AMPK in the PTEN–Pink1-associated
regulation of cardiac geometry and function. To this end, the present
study was designed to examine the possible link among PTEN, Pink1,
AMPK and autophagy in the regulation of cardiac geometry and
contractile function. A cardiomyocyte-speciﬁc knockout of PTEN murine
model was generated recently in our laboratory displaying moderate
cardiac dysfunction [9]. To evaluate the causal relationship between
Pink1 and AMPK, Pink1 was knocked down in H9C2 cells prior to the
assessment of AMPK phosphorylation. To better elucidate the role of
AMPK in PTEN deletion-induced cardiac anomalies, if any, the AMPK
activator metformin was administered in vivo to provide the proof-of-
concept evidence for the role of AMPK in PTEN deletion-induced cardiac
responses. Status of autophagy and autophagic ﬂux were monitored
using the autophagic protein makers LC3B isoforms and the
autophagosome adaptor protein p62. Our data demonstrated that PTEN
deletion may contribute to loss of Pink1–AMPK signaling and cardiac
pathological changes in association with impaired autophagy and
autophagic ﬂux.
2. Materials and methods
2.1. Generation of cardiomyocyte-speciﬁc PTEN knockout mice andmetformin
treatment
All animal procedures carried out in this studywere approved by the
Animal Care and Use Committee at the University of Wyoming
(Laramie, WY) and was in compliance with the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of
Health (NIH publication no. 85–23, revised 1996). Cardiomyocyte-
speciﬁc PTEN(ﬂox/ﬂox)/α-myosin heavy chain (α-MHC) Cremice, hence-
forth referred to as CM PTENKO, were generated as reported previously.
The wild-type (WT) PTEN (−/−), heterozygous PTEN (+/−) and
ﬂoxed PTEN (+/+) alleles were analyzed by PCR with tail DNA [9].
Only PTEN(ﬂox/ﬂox) littermates negative for α-MHC Cre were used as
WT.Micewere housed in a 12:12 hour light–dark cycle with free access
to food and drinking water. Metformin was administered in the
drinking water (200 mg/kg/d, Sigma Cat# D150959) as previously
described for one month [16].
2.2. Echocardiographic assessment
Cardiac geometry and function were evaluated in anesthetized
(ketamine 80 mg/kg and xylazine 12 mg/kg, i.p.) mice using the 2-D
guided M-mode echocardiography (Philips Sonos 5500) equipped
with a 15–6 MHz linear transducer. Left ventricular (LV) anterior and
posterior wall dimensions during diastole and systole were recorded
from three consecutive cycles in M-mode using method adopted by
the American Society of Echocardiography. Fractional shortening was
calculated from LV end-diastolic (EDD) and end-systolic (ESD)diameters using the equation (EDD − ESD) / EDD. Heart rates were
averaged over 10 cycles [17].2.3. Isolation of murine cardiomyocytes
Cardiomyocytes were isolated as previously described [17]. Mice
were anesthetized with ketamine/xylazine, hearts were removed and
perfused with oxygenated (5% CO2–95% O2) Krebs–Henseleit bicarbon-
ate (KHB) buffer at 37 °C containing (in mM) 118 NaCl, 4.7 KCl, 1.2
KH2PO4, 25 NaHCO3, 10 HEPES and 11.1 glucose. Hearts were then
perfused with KHB buffer containing 10 mg/ml Liberase Blendzyme
(Roche Diagnostics, Indianapolis IN) for 15 min. Left ventricles were
subsequently minced, dispersing the cardiomyocytes. Ca2+ was added
back slowly to a ﬁnal concentration of 1.25 mM. Only rod shaped
myocytes without spontaneous contractions were used for analysis
[18]. To assess the role of AMPK and autophagy in PTEN knockout-
induced cardiomyocyte contractile dysfunction, cardiomyocytes from
adult PTEN−/− mice were treated with metformin (50 μM) [19,20],
the mTOR inhibitor rapamycin (5 μM) to stimulate autophagy [21], or
both, at 37 °C for 4 h prior to the assessment of cardiomyocyte
mechanical function.2.4. Cardiomyocyte mechanics and intracellular Ca2+ handling
Cellmechanics and Ca2+ propertieswere assessed using an IonOptix
softedge detection system. Myocytes were placed on a chamber
mounted on an Olympus IX-70 microscope stage in a buffer containing
(in mM) 131 NaCl, 4 KCl, 1 CaCl2, 1 MgCl2, 10 glucose and 10 HEPES.
Myocytes were then stimulated at 0.5 Hz and the following indices
were evaluated: peak shortening (PS), time-to-PS (TPS), time-to-90%
relengthening (TR90), and maximal velocities of shortening/
relengthening (±dL/dt). For Ca2+ analysis, myocytes were loaded
with fura-2/AM (0.5 μM) for 10 min. A duel excitation ﬂuorescence
photomultiplier system (IonOptix) was used to measure ﬂuorescence
intensity. Myocytes were placed on the microscope as described above
for cell mechanics, and exposed to light emitted by a 75 W mercury
lamp passed through either a 360- or 380-nm ﬁlter. While stimulated
at 0.5 Hz, ﬂuorescence emissions were detected by a photomultiplier
tube between 480 nm and 520 nm after initial illumination at 360 nm
for 0.5 s followed by380 nm for the remaining time. Changes in intracel-
lular Ca2+ were calculated by the ratio of the ﬂuorescence intensity at
two wavelengths while single exponential curve ﬁtting was used for
Ca2+ decay rate. These techniques have been previously described
[17,22].2.5. Myocardial histology and superoxide detection
Procedure was conducted as described [23]. Hearts were excised
from anesthetized animals, washed with PBS, cut to expose cross
section of left ventricle and embedded in O.C.T. embedding compound
(Tissue-Tek, Torrence, CA) stored at−80 °C until analysis. Five microli-
ters of tissue sections were cut, placed on slides and washed 1× with
PBS. FITC-conjugated lectin was added to the slides and kept at 37 °C
in a humidiﬁed chamber in the dark for 2 h. Slides were washed 2×
with PBS and mounted with Prolong Gold Antifade reagent. For super-
oxide measurement, 7-μm tissue sections were cut from heart sections.
Slides were incubated with dihydroethidium (DHE, 3 μM, Molecular
Probes) for 60 min at room temperature [24]. After being washed
with PBS, tissues were stained with DAPI (1 μg/ml, Sigma, D9564) for
5min at room temperature. Next, sectionsweremounted with ProLong
Gold Antifade (Life Technologies). Images were acquired using a Zeiss
710 laser scanning confocal microscope. Fluorescence intensity per
nucleus was calculated using Image J [24].
Fig. 1. Cardiomyocyte-speciﬁc PTEN knockout affects myocardial PINK1 and AMPK. A: Representative PCR gels containing ﬂoxed PTEN and theα-myosin heavy chain (α-MHC) Cre trans-
gene; B: Immunoblot depicting PTEN expression in PTEN KOmurine whole hearts; C: Immunoblot showing PTEN expression in cardiomyocytes isolated from PTEN KOmurine hearts; D:
Pink 1 expression; E: AMPK phosphorylation; F: Intracellular ATP levels in H9C2 cells treated with scrambled or Pink1 siRNA; G: Representative gel blots of Pink1 and AMPK (total and
phosphorylated) in control, scrambled siRNA and Pink1 siRNA groups; and H: AMPK phosphorylation (pAMPK-to-AMPK ratio) in control, scrambled siRNA and Pink1 siRNA cell groups.
Mean ± SEM, n = 3 (panels D–E) and 8 (panels F and H), *p b 0.05 vs. Wild Type or Control group, #p b 0.05 vs. scrambled RNA group.
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Heart tissue was homogenized in RIPA (Millipore, Billerica MA)
lysis buffer and centrifuged at 12,000 g for 20 min at 4 °C. Samples
containing equal amounts of protein were separated on a 10 or 12%
SDS-polyacrylamide gel in a mini-gel apparatus (Mini-PROTEAN II,
Bio-Rad). Proteins were then transferred to nitrocellulose
membranes and subsequently blocked with 5% BSA in tris buffered
saline (TBS)-tween 20. Membranes were incubated overnight at
4 °C in primary antibodies: anti-PTEN (Cell Signaling, Cat#9552),
anti-pAMPK (T172, Cell Signaling, Cat#2535), anti-AMPK (Cell
Signaling, Cat#2532), anti-p62 (Enzo Life Sciences, Cat#GP62-C),
anti-LC3B (Cell Signaling, Cat#3868S), anti-GAPDH (Cell Signaling,
Cat#2118 L), and anti-Pink1 (Abcam, Cat#ab23707). Blots were
washed with TBS-Tween 20 and incubated with horseradish
peroxidase (HRP) conjugated secondary antibody. Membranes
were subsequently washed and exposed by enzymatic chemilumi-
nescence in a GelDoc system (Bio-Rad) [25].2.7. Cell culture and siRNA treatment
Rat neonatal H9C2 myoblast cells were grown in Dulbecco's modi-
ﬁed Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin–streptomycin under a humidiﬁed atmo-
sphere of 5% CO2 in air and maintained at low conﬂuence. When cellsreached 80% conﬂuence, Pink1 targeted siRNA (100 nM, Qiagen,
Cat#68943) was transfected using DharmaFECT (Dharmacon) transfec-
tion reagent in DMEM with 10% FBS for 72 h [26].
2.8. ATP measurement
Intracellular ATP concentration was measured as previously
described [27]. Brieﬂy, fresh H9C2 cells were homogenized with
the lysis buffer. ATP Determination Kit (Molecular Probes, A22066)
was purchased to measure the intracellular ATP level. In
each sample, protein concentration was measured to evaluate ATP
concentration.
2.9. Statistical analysis
Data are presented as Mean ± SEM. Statistical signiﬁcance was
determined by 2-tailed Student's t-test in cases of two groups, and
one way ANOVA followed by Tukey's post hoc analysis in cases of 3
groups. Signiﬁcance for each analysis was judged as p b 0.05.
3. Results
3.1. PTEN deletion results in cardiac hypertrophy and dysfunction
Crossingmice expressingα-MHCCrewith PTEN(ﬂox/ﬂox) led to ~75%
reduction of PTEN protein expression in whole hearts and ~85%
Fig. 2. Effect of AMPK activation with metformin (200 mg/kg/d, drinking water for 4 weeks) on PTEN knockout-induced cardiac geometric and functional anomalies. A: Representative
lectin staining of myocardial sections in wild type, PTEN knockout and PTEN knockout plus metformin mouse groups. B: Pooled data depicting cross sectional area from lectin staining;
C: Heart weight (HW) to body weight (BW) ratio; D: Representative echocardiographic images in wild type, PTEN knockout and PTEN knockout with metformin treatment mice; E:
Fractional shortening. Mean ± SEM n= 4–7 mice per group.
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difference in the PTEN abundance attributed to non-cardiomyocyte
components present in whole heart homogenates (e.g., ﬁbroblasts,
endothelial cells). Lectin staining and cross sectional area analysis
demonstrated overt cardiac hypertrophy following PTEN deletion
(Fig. 2A, B). This is conﬁrmed by a signiﬁcant rise in the heart-to-body
weight ratio in PTEN KO mice (Fig. 2C). Cardiac function assessed
using echocardiography revealed subtle although signiﬁcant decline in
fractional shortening following PTEN deletion (Fig. 2D, E). These data
collectively support a pathological phenotype in hearts following
cardiomyocyte-speciﬁc PTEN knockout.3.2. Decreased PTEN/Pink1 increased intracellular ATP levels and decreased
pAMPK
To examine possible signaling mechanism of PTEN knockout-
induced cardiac anomalies, two important signaling regulators of
cardiac function, Pink1 and AMPK, were evaluated. PTEN deﬁcient
mice displayed decreased levels of Pink1 and AMPK phosphorylation
in the heart (Fig. 1D, E). To further evaluate the cause-effect relationship
between Pink1 and AMPK, siRNA directed against Pink1 was utilized in
H9C2 cells. Seventy-two hours of Pink1 siRNA treatment led to a
signiﬁcant removal of the Pink1 protein in H9C2 cells. Interestingly,
Fig. 3. Effect of AMPK activation with metformin (200 mg/kg/d, drinking water for 4 weeks) on PTEN knockout-induced cardiomyocyte contractile anomalies. A: Representative cell
shortening traces from wild type, PTEN knockout and PTEN knockout with metformin treatment groups; B: Peak shortening (normalized to resting cell length); C: Maximum velocity
of shortening (+dL/dt); D: Maximum velocity of relengthening (−dL/dt); E: Time-to-90% relengthening (TR90); and F: Time-to-PS (TPS). Mean ± SEM, n = 139–200 cells from 3
mice per group, *p b 0.05 vs. Wild Type, #p b 0.05 vs. PTEN KO group.
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suppressed AMPK phosphorylation, suggesting a causative relationship
between Pink1 and AMPK (Fig. 1F, G).
3.3. PTEN deletion-induced whole heart dysfunction and hypertrophy is
AMPK dependent
To test the role of suppressed AMPK phosphorylation in PTEN
knockout-induced cardiac dysfunction, The AMPK activator metformin
was administered (200 mg/kg/d in drinking water for 4 weeks) in
PTEN deﬁcient mice prior to assessment of cardiac morphology and
function. Cross sectional area analysis revealed an increased cardiomyo-
cyte size in PTEN knockout, the effect of which was partially attenuatedby metformin treatment. Consistently, the enhanced heart weight in
PTEN knockout mice was also abrogated by metformin. Echocardio-
graphic analysis depicted that PTEN knockout signiﬁcantly suppressed
fractional shortening, the effect of which was mitigated by metformin
(Fig. 2).
3.4. Cardiomyocyte mechanical dysfunction is reversed by AMPK activation
To examine the role of individual cardiomyocytes in PTEN deletion-
and/or metformin-induced cardiac anomalies, cardiomyocyte contractile
function and intracellular Ca2+ handling were evaluated. Our results
depicted that PTEN deletion induced overt cardiomyocyte contractile
dysfunction as manifested by depressed peak shortening, maximal
Fig. 4. Effect of AMPK activation withmetformin (200 mg/kg/d, drinking water for 4 weeks) on PTEN knockout-induced intracellular Ca2+ handling in cardiomyocytes. A: Representative
intracellular Ca2+ transient traces fromwild type, PTEN knockout and PTEN knockout with metformin treatment groups; B: Resting fura-2 ﬂuorescence intensity (FFI); C: Electronically-
stimulated rise in FFI (ΔFFI); and D: Intracellular Ca2+ decay rate. Mean ± SEM, n = 58–60 cells from 3 mice per group, *p b 0.05 vs. Wild Type, #p b 0.05 vs. PTEN KO group.
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of whichwere nulliﬁed bymetformin (Fig. 3). Assessment of intracellular
Ca2+ transients revealed that PTEN deletion signiﬁcantly depressed
baseline and electrically-stimulated rise in intracellular Ca2+ (baseline
FFI and ΔFFI, respectively) without affecting the intracellular Ca2+
decay rate. Metformin effectively reversed PTEN deletion-induced drop
in ΔFFI without affecting baseline FFI and intracellular Ca2+ decay
(Fig. 4).3.5. Impaired AMPK activation impacts autophagy and increases superoxide
accumulation in PTEN deﬁcient mice
To explore the mechanism of action behind metformin-offered
beneﬁcial effect against PTEN deletion, we went on to examine
autophagy, an essential cellular event driven by AMPK with a known
role in cardiac pathologies including ischemia, hypertrophy and heart
failure [15]. Cardiomyocyte-speciﬁc knockout of PTEN overtly
suppressed phosphorylation of AMPK and autophagy as evidenced by
decreased LC3BII expression and LC3-II/I ratio and elevated
accumulation of the autophagosome cargo protein p62, the effects of
which were abrogated or signiﬁcantly attenuated by metformin
(Fig. 5A–F). Furthermore, PTEN knockout dramatically increased the
phosphorylation of ULK1 at Ser757 in the heats, the effect of which
was alleviated by metformin treatment (Fig. 5A, G). Given that reactive
oxygen species accumulation is common in heart failure and was
recently reported in PINK1 deﬁciency [11], we evaluated the levels of
superoxide, serving both as a potent inducer and a degradation target
for autophagy [28–30]. Our results revealed a drastic rise in superoxide
levels inmyocardium from PTEN deﬁcientmice, the effect of whichwas
partially although signiﬁcantly attenuated by metformin (Fig. 5H, I).
These results favored disrupted autophagy in particular autophagic
ﬂux following PTEN deletion possibly associatedwith impaired removal
of reactive oxygen species. Activation of AMPK using metformin iscapable of alleviating PTEN deletion-induced defect in autophagy and
superoxide accumulation.
3.6. Cardiomyocyte mechanical dysfunction is reversed by rapamycin
To better elucidate the cause–effect relationship between AMPK and
autophagy in PTEN knockout-induced cardiac contractile dysfunction,
freshly isolated cardiomyocytes from PTEN−/− mice were incubated
with the AMPK activator metformin, the autophagy inducer rapamycin,
or both, for 4 h prior to assessment of cardiomyocyte contractile
function. Our results shown in Fig. 6 demonstrated that metformin
and rapamycin signiﬁcantly attenuated PTEN knockout-induced
cardiomyocyte mechanical anomalies, with little additive effect
between the two.
4. Discussion
Findings from this study depicted a novel possible sequential
pathway connecting PTEN, Pink1, AMPK and autophagy in the
regulation of cardiac geometry and function. Our data revealed overt car-
diac hypertrophy and contractile dysfunction following cardiomyocyte-
speciﬁc knockout of PTEN. PTEN knockout-induced cardiac hypertrophy
is consistent with the earlier ﬁnding from the skeletal muscle PTEN
genetic model and is not entirely unexpected due to the negative effect
of PTEN on Akt signaling [31]. Conﬂicting data have been observed with
regards to the outcome of Akt overactivation on cardiac homeostasis.
Overexpression of Akt has been reported to elicit little [32] or hypercon-
tractile [33] effect on the basal cardiac function. Earlier evidence has
demonstrated the involvement of the overactive G-protein coupled
receptor PI3Kγ signaling and reduced cyclic AMP production in PTEN
deﬁcient hearts [7].
Pink1 has recently emerged as an excellent candidate for a PI3K/Akt
alternative pathway involved in the governance of cardiac function in
the PTEN deﬁcient hearts. Pink1 was initially recognized for its unique
Fig. 5. Effect of AMPK activation withmetformin (200 mg/kg/d, drinkingwater for 4 weeks) on PTEN knockout-induced changes in autophagy and ROS generation. A: Representative gel
blots depicting levels of total and phosphorylated AMPK, p62, LC3B, and phosphorylated ULK1 in wild type, PTEN knockout and PTEN knockout with metformin treatment groups; B:
pAMPK-to-AMPK ratio; C: p62 expression; D: LC3B-I expression; E: LC3B-II expression; F: LC3B-II to LC3B-I ratio; G: pULK1-to-ULK1 ratio; H: Representative images fromWT, PTENknock-
outmice treatedwith orwithoutmetformin stainedwith DHE and DAPI. OxidizedDHE intercalates into DNA and the nuclei appear in red; and I: Quantiﬁcation of the DHE-positive nuclei.
Mean ± SEM, n = 4–7 (panels B–F) and 5–10 mice (panel H) per group, *p b 0.05 vs. Wild Type group; #p b 0.05 vs. PTEN KO group.
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suggested that lack of Pink1 directly leads to impaired mitochondrial
function and generation of ROS [35]. More importantly, recent studies
indicate that PINK1 possesses an indispensable role in themaintenance
of cardiac homeostasis [11]. Concomitant heart dysfunction and
hypertrophy along with elevated ROS generation were revealed in
Pink1 deﬁcient mice [11]. Furthermore, decreased levels of PINK1
were found in patients with end-stage heart failure, suggesting that
PINK1 reduction might contribute to the development of heart failure
[11]. Data from our study suggested signiﬁcantly decreased Pink1 levels
in PTEN knockout mice, implicating a possible role of lost Pink1 signal-
ing in PTEN deletion. This ﬁnding is consistent with an earlier report in
haploinsufﬁcient PTEN hearts where decreased Pink1 was seen [36].
Perhaps the most intriguing data from our study was decreased AMPK
phosphorylation following PTEN deletion. This ﬁnding prompted the
speculation that AMPK phosphorylation may occur as a downstream
target of Pink1, which was consolidated using the Pink1 siRNA
knockdown in H9C2 cells where Pink1 knockdown was sufﬁcient to
suppress AMPK phosphorylation. A direct link between Pink1 and
AMPK phosphorylation has not been reported previously.
AMPK has been identiﬁed as a target in themanagement of multiple
heart diseases [37]. For example, targeting insufﬁcient AMPK phosphor-
ylation is known to protect against ischemia reperfusion-induced injury[38,39]. Likewise, impaired AMPK activation is prevalent in diabetic
heart while reactivation with metformin recovers function in diabetes
through preserving autophagy [16,40]. In our hands, stimulating
AMPK with metformin restored myocardial dysfunction following
PTEN knockout. Our study further demonstrated preserved intracellular
Ca2+ handling against PTEN knockout following metformin treatment.
Recently Oliveira and colleagues showed that AMPK phosphorylation
of troponin I increases myoﬁlament sensitivity to Ca2+ [41]. Thus
impaired AMPK activity may underscore myocardial dysfunction in
isolated cardiomyocytes under PTEN deﬁciency.
Our result revealed overt cardiac hypertrophy with cardiomyocyte-
speciﬁc deletion of PTEN, consistent with the ﬁndings from AMPK
deﬁciency. In our hands, AMPK activation using metformin
effectively alleviated the PTEN deletion-induced cardiac hypertrophy
(heart weight and cross sectional area), consistent with the anti-
hypertrophic property of AMPK. It has been shown that AMPK
activation using AICAR reversed pressure overload-induced cardiac
hypertrophy [42]. Along the same line, metformin also inhibits
hypertrophic protein synthesis in neonatal rat cardiomyocytes [43]. It
may be speculated that the enhanced Akt phosphorylation (as a result
of PTEN knockout) in conjunction with lost AMPK activation contribute
to cardiac hypertrophy in PTEN deﬁciency. AMPK is known to serve as a
check point against Akt in cardiac hypertrophy.
Fig. 6. Effect ofmetformin (Met, 50 μM) and rapamycin (Rapa, 5 μM), or both, on PTEN knockout-induced cardiomyocyte contractile anomalies. Cardiomyocytes from adult PTEN−/−mice
were treatedwithmetformin (50 μM),mTOR inhibitor (autophagy inducer) rapamycin (5 μM), or both, at 37 °C for 4 h prior to assessment of cardiomyocytemechanical function. A: Rest-
ing cell length; B: Peak shortening (normalized to resting cell length); C: Maximum velocity of shortening (+dL/dt); D: Maximum velocity of relengthening (−dL/dt); E: Time-to-90%
relengthening (TR90); and F: Time-to-PS (TPS). Mean ± SEM, n = 100 cells from 3 mice per group, *p b 0.05 vs. Wild Type, #p b 0.05 vs. PTEN KO group.
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of cardiac function [44]. Autophagy is protective under stress conditions
whereas excess autophagy impairs cell function. Activation of AMPK
inhibits mTORC1 activity by phosphorylating TSC2 and Raptor to turn
on autophagy [25,45–47]. Alternatively, AMPK may facilitate
autophagosome initiation by promoting ULK1 through phosphorylation
at Ser317, Ser777, Ser467, Ser555, Ser574 and Ser637 sites [48,49]. Once
phosphorylated, ULK1 phosphorylates autophagy initiation complexes
Atg13 and FIP200 [50]. On the other hand, phosphorylation of ULK1 at
Ser757 has been found to suppress autophagy [9]. Data from our study
revealed impaired AMPK activation and autophagy in PTEN deﬁciency
mice accompaniedwith cardiac hypertrophy and impaired contractility,
suggesting a possible role of AMPK in PTEN deﬁciency-induced cardiac
anomalies. This received support from the fact that AMPK activation
usingmetformin rescued PTEN deﬁciency-induced cardiac hypertrophy
and contractile dysfunction. The beneﬁcial effect of metformin is closely
accompanied with restored autophagy and autophagic ﬂux as
evidenced by LC3B isozyme conversion and p62. Our ﬁnding suggested
that Pink1may be the upstream regulator for AMPK, en route to autoph-
agy governance. Pink1 has been shown to promote mitophagy [51,52]
although its precise role in cardiac autophagy is unknown. Our study
further revealed that metformin elicited its beneﬁcial effect on cardiac
geometry, function, autophagy, and superoxide accumulation in PTEN
deﬁcient murine hearts. During stress, autophagy may step up to
remove abnormal protein aggregates, oxidized proteins, damaged
mitochondria and other cellular components, ultimately preserving
cell physiological function [30]. Our data indicated that metformin
restores PTEN knockout-induced cardiac anomalies and autophagy,
partially through alleviating superoxide accumulation. Last but not
least, the fact that metformin and rapamycin each rescued against
PTEN deletion-induced cardiomyocyte contractile dysfunction with
little additive effect indicates a likely sequential correlation between
AMPK activation and autophagy.In conclusion, our study provided the evidence that cardiomyocyte-
speciﬁc PTEN knockout elicited cardiac hypertrophy and contractile
dysfunction associated with interrupted autophagy and autophagic
ﬂux. Our data further depicted a role of Pink1 and AMPK in PTEN
knockout-induced cardiac anomalies. Activation of AMPK usingmetfor-
min rescued against PTEN deletion-induced changes in myocardial
geometry, function and autophagy, supporting a role of AMPK in PTEN
deletion-induced cardiac anomalies. Although it is somewhat
premature to consolidate for a unique role of Pink1–AMPK in the
cardiomyocyte-speciﬁc PTEN deletion-induced hypertrophic cardiomy-
opathy, our results should shed some lights towards a better
understanding for a role of PTEN in the maintenance of myocardial
geometry and function.
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